Recent Advances in Advance Prostate Cancer

Prostate cancer being the second most frequent and fifth leading cause of mortality has led to conduct of many new clinical trials and development of newer therapeutic agents. In the last decade with better understanding of biology of disease there is dramatic improvement and sea change in survival outcomes in advanced prostate cancer with advent of chemotherapy, targeted therapy immunotherapy besides androgen deprivation therapy. Varied newer drugs and combinations in recent years have improved the outcome of prostate cancer in terms of both overall survival(OS) and metastases free survival(MFS). Some of the latest drugs which have cleared regulatory approval are Abiraterone, Enzalutamide,Apulatamide, Sipuleucel-T etc. However still more needs to be explored to negate and overcome the resistant mechanisms. Here in this article we have summarized the varied newer and recent developments in advanced prostate cancer.